This proposal has 2 options that would both have effect from 1 July 2023.

Option 1

This option would legalise the production and sale of recreational cannabis in Australia through a tightly regulated model and by establishing the Cannabis Australia National Agency (CANA).

1.  The CANA would:

This proposal has 2 options that would both have effect from 1 July 2023.

Option 1

This option would legalise the production and sale of recreational cannabis in Australia through a tightly regulated model and by establishing the Cannabis Australia National Agency (CANA).

1.  The CANA would:

This proposal has 2 options that would both have effect from 1 July 2023.

Option 1

This option would legalise the production and sale of recreational cannabis in Australia through a tightly regulated model and by establishing the Cannabis Australia National Agency (CANA).

1.  The CANA would:

This proposal has 2 options that would both have effect from 1 July 2023.

Option 1

This option would legalise the production and sale of recreational cannabis in Australia through a tightly regulated model and by establishing the Cannabis Australia National Agency (CANA).

1.  The CANA would:

The Commonwealth Government would provide dedicated funding to state and territory governments to fund the dispensing fees for all patients receiving opioid dependence treatment (methadone, buprenorphine and buprenorphine‐naloxone) and any associated administration costs.

The dispensing fee funding would be a standardised amount paid by states and territories to dosing point sites (mostly community pharmacies) for each dose of opioid dependence treatment.

The Commonwealth Government would provide dedicated funding to state and territory governments to fund the dispensing fees for all patients receiving opioid dependence treatment (methadone, buprenorphine and buprenorphine‐naloxone) and any associated administration costs.

The dispensing fee funding would be a standardised amount paid by states and territories to dosing point sites (mostly community pharmacies) for each dose of opioid dependence treatment.

The Commonwealth Government would provide dedicated funding to state and territory governments to fund the dispensing fees for all patients receiving opioid dependence treatment (methadone, buprenorphine and buprenorphine‐naloxone) and any associated administration costs.

The dispensing fee funding would be a standardised amount paid by states and territories to dosing point sites (mostly community pharmacies) for each dose of opioid dependence treatment.

The Commonwealth Government would provide dedicated funding to state and territory governments to fund the dispensing fees for all patients receiving opioid dependence treatment (methadone, buprenorphine and buprenorphine‐naloxone) and any associated administration costs.

The dispensing fee funding would be a standardised amount paid by states and territories to dosing point sites (mostly community pharmacies) for each dose of opioid dependence treatment.

The proposal consists of 7 components and would commence from 1 July 2022.

Component 1 would fund a scoping study to determine the areas of greatest need and types of services, and suitable locations for new medically supervised injecting centres (the centres) in Australian capital cities.

Component 2 would establish one new centre in each capital city. Funding would be ongoing.

The proposal consists of 7 components and would commence from 1 July 2022.

Component 1 would fund a scoping study to determine the areas of greatest need and types of services, and suitable locations for new medically supervised injecting centres (the centres) in Australian capital cities.

Component 2 would establish one new centre in each capital city. Funding would be ongoing.